Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03532542
Other study ID # 4045-302
Secondary ID 2017-004625-32
Status Terminated
Phase Phase 3
First received
Last updated
Start date August 2, 2018
Est. completion date July 26, 2023

Study information

Verified date August 2023
Source Sarepta Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).


Recruitment information / eligibility

Status Terminated
Enrollment 171
Est. completion date July 26, 2023
Est. primary completion date July 26, 2023
Accepts healthy volunteers No
Gender Male
Age group 7 Years to 23 Years
Eligibility Inclusion Criteria: - Completed a clinical trial evaluating casimersen or golodirsen, per protocol. - Is between 7 and 23 years of age, inclusive, at enrollment. Other inclusion/exclusion criteria apply.

Study Design


Intervention

Drug:
Casimersen
Casimersen solution for IV infusion
Golodirsen
Golodirsen solution for IV infusion

Locations

Country Name City State
Belgium UZ Gent Gent Oost-Vlaanderen
Belgium UZ Leuven Leuven
Bulgaria University Multiprofile Hospital for active treatment Aleksandrovska EAD Clinic of Neurological Diseases Sofia
Canada Alberta Children's Hospital Calgary Alberta
Canada Children's Hospital of Eastern Ontario Ottawa Ontario
Czechia Fakultni nemocnice Brno, Klinika detske neurologie LF MU a FN Brno Brno
Czechia Fakultni nemocnice v Motole Praha 5
France Hotel Dieu- CHU Nantes Nantes Cedex
France Hôpital Armand Trousseau Paris
Germany Universitatsklinikum Essen Essen Nordrhein-Westfalen
Germany Universitatsklinikum Freiberg Freiburg Baden-Wurttemberg
Israel Schneider Children's Medical Center of Israel Petach Tikva
Italy Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant' Anna Cona
Italy UOSD Centro Traslazionale di Miologia e Patologie Neurogenerative Genova Liguria
Italy Fondazione Policlinico Universitario A Gemelli Milano
Poland Uniwersyteckie Centrum Kliniczne, Klinica Neurologii Rozwojowej Gdansk
Poland Samodzielny Publiczny Centralny Szpital Kliniczny Warsaw Mazowieckie
Spain Hospital de La Santa Creu i Sant Pau Barcelona Cataluña
Spain Hospital Sant Joan de Deu Barcelona
Spain Hospital Universitari i Politecnic La Fe de Valencia Valencia
Sweden Provningsenhet Barn, Drottning Silvias Och Ungdomssjukhus Goteborg
United Kingdom Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust Leeds
United Kingdom Alder Hey Children's NHS Foundation Trust Liverpool
United Kingdom Great Ormond Street Hospital (GOSH) London
United Kingdom Royal Victoria Infirmary Newcastle Upon Tyne
United States Rare Disease Research, LLC Atlanta Georgia
United States Kennedy Krieger Institute Baltimore Maryland
United States Boston Children's Hospital Boston Massachusetts
United States Ann and Robert H Lurie Childrens Hospital of Chicago Chicago Illinois
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Abigail Wexner Research Institute at Nationwide Children's Hospital Columbus Ohio
United States Children's Medical Center Dallas Dallas Texas
United States UF Health: University of Florida Clinical Research Center Gainesville Florida
United States NW Florida Clinical Research Group, LLC Gulf Breeze Florida
United States Texas Children's Hospital Houston Texas
United States University of Iowa Childrens Hospital Iowa City Iowa
United States University of Kansas Medical Center Kansas City Kansas
United States Las Vegas Clinic Las Vegas Nevada
United States Children's Hospital Los Angeles Los Angeles California
United States University of California Los Angeles Los Angeles California
United States Children's Hopsital of Wisconsin, Corporate Center Suite 540 Milwaukee Wisconsin
United States Children's Hospital of The King's Daughters Norfolk Virginia
United States Stanford Neuroscience Health Center Palo Alto California
United States Neuromuscular Research Center Phoenix Arizona
United States Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania
United States Shriners Hospital for Children Portland Oregon
United States University of Rochester Medical Center - Department of Neurology Rochester New York
United States St. Louis Children's Hospital Saint Louis Missouri
United States University of Utah - PPDS Salt Lake City Utah
United States Rady Children's Hospital- San Diego San Diego California

Sponsors (1)

Lead Sponsor Collaborator
Sarepta Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  Belgium,  Bulgaria,  Canada,  Czechia,  France,  Germany,  Israel,  Italy,  Poland,  Spain,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients With Serious Adverse Events (SAEs) Up to 30 days after the last infusion of study drug (assessed up to 148 weeks)
See also
  Status Clinical Trial Phase
Completed NCT05575648 - Dual Task in Duchenne Muscular Dystrophy N/A
Terminated NCT03907072 - Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy Phase 2/Phase 3
Completed NCT04335942 - Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor N/A
Active, not recruiting NCT04906460 - Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53) Phase 1/Phase 2
Active, not recruiting NCT02500381 - Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) Phase 3
Enrolling by invitation NCT05967351 - A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study Phase 3
Recruiting NCT03067831 - Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy Phase 1/Phase 2
Recruiting NCT01834040 - Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy Phase 1/Phase 2
Completed NCT02246478 - A Study of TAS-205 for Duchenne Muscular Dystrophy Phase 1
Active, not recruiting NCT01772043 - Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping N/A
Terminated NCT01168908 - Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Phase 2
Completed NCT00758225 - Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension) Phase 2
Completed NCT03680365 - Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Recruiting NCT03513367 - The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.
Recruiting NCT05712447 - Duchenne Muscular Dystrophy Video Assessment Registry
Recruiting NCT01484678 - Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Completed NCT03319030 - Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)
Terminated NCT01753804 - A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy. N/A
Completed NCT02530905 - Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients Phase 1
Terminated NCT04708314 - An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy Phase 4